MXPA05011221A - Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi. - Google Patents
Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi.Info
- Publication number
- MXPA05011221A MXPA05011221A MXPA05011221A MXPA05011221A MXPA05011221A MX PA05011221 A MXPA05011221 A MX PA05011221A MX PA05011221 A MXPA05011221 A MX PA05011221A MX PA05011221 A MXPA05011221 A MX PA05011221A MX PA05011221 A MXPA05011221 A MX PA05011221A
- Authority
- MX
- Mexico
- Prior art keywords
- angiopoietin
- compositions
- methods
- tie2
- sirna inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Abstract
La interferencia de ARN usando ARN pequeno de interferencia pequeno que son especificos para ARNm producidos a partir de genes Ang 1, Ang 2 o Tie 2 inhiben la expresion de estos genes; enfermedades que involucran angiogenesis mediada con Ang 1, Ang 2 o Tie 2, tales como enfermedades inflamatorias y autoinmunes, retinopatia diabetica, degeneracion macular relacionada con la edad y muchos tipos de cancer, se pueden tratar al administrar el ARN pequeno de interferencia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46398103P | 2003-04-18 | 2003-04-18 | |
PCT/US2004/012072 WO2004094606A2 (en) | 2003-04-18 | 2004-04-19 | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05011221A true MXPA05011221A (es) | 2006-02-17 |
Family
ID=33310844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05011221A MXPA05011221A (es) | 2003-04-18 | 2004-04-19 | Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi. |
Country Status (7)
Country | Link |
---|---|
US (2) | US7994305B2 (es) |
EP (1) | EP1615943A4 (es) |
JP (1) | JP2006523464A (es) |
AU (1) | AU2004233043A1 (es) |
CA (1) | CA2522730A1 (es) |
MX (1) | MXPA05011221A (es) |
WO (1) | WO2004094606A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050159380A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA) |
US20090137507A1 (en) * | 2002-02-20 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF ANGIOPOIETIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
MXPA04010282A (es) * | 2002-04-18 | 2005-08-18 | Acuity Pharmaceuticals Inc | Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo. |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
CA2522730A1 (en) | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2 |
EP1789447B1 (en) | 2004-08-16 | 2012-04-25 | Immune Disease Institute, Inc. | Method of delivering rna interference and uses thereof |
US20090130212A1 (en) * | 2006-05-15 | 2009-05-21 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
JP5004505B2 (ja) * | 2006-05-18 | 2012-08-22 | 株式会社サンギ | 口腔用組成物 |
EP2029746B1 (en) * | 2006-06-12 | 2012-07-04 | Exegenics, Inc., D/b/a Opko Health, Inc. | Compositions and methods for sirna inhibition of angiogenesis |
US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
WO2008109488A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting angpt2 gene expression and uses thereof |
WO2008109369A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
WO2009008990A2 (en) * | 2007-07-06 | 2009-01-15 | Intradigm Corporation | Methods and compositions for treatment of cancer and other angiogenesis - related diseases |
CA2729012A1 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
SG171952A1 (en) | 2008-12-04 | 2011-07-28 | Opko Ophthalmics Llc | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
JP2012517815A (ja) * | 2009-02-18 | 2012-08-09 | サイレンス・セラピューティクス・アーゲー | Ang2の発現を阻害するための手段 |
EP2483460B1 (en) | 2009-09-28 | 2015-09-02 | Trustees Of Tufts College | Method to prepare drawn silk egel fibers |
CA2819635A1 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
CN104062432B (zh) * | 2013-03-22 | 2016-01-20 | 中山大学 | ang2在制备ECTC血管类型肝癌诊断试剂及治疗药物中的应用 |
KR20230037676A (ko) | 2014-09-05 | 2023-03-16 | 피오 파마슈티칼스 코프. | Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법 |
CN109154002B (zh) | 2016-03-01 | 2022-08-30 | 佛罗里达大学研究基金会有限公司 | 用于治疗显性视网膜色素变性的aav载体 |
PT109454A (pt) | 2016-06-14 | 2017-12-14 | Phyzat Biopharmaceuticals Lda | Ácidos nucleicos de interferência e composições que os compreendem |
WO2021219708A1 (en) | 2020-04-28 | 2021-11-04 | Phyzat Biopharmaceuticals, Lda | Sina molecules, methods of production and uses thereof |
US20210348167A1 (en) | 2020-05-09 | 2021-11-11 | Phyzat Biopharmaceuticals, Lda | siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF |
EP4247952A2 (en) | 2020-11-23 | 2023-09-27 | Phyzat Biopharmaceuticals, Lda. | Sina molecules, methods of production and uses thereof |
AU2022214429A1 (en) | 2021-02-01 | 2023-09-14 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US6121000A (en) * | 1999-02-11 | 2000-09-19 | Genesense Technologies, Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
CA2393646A1 (en) * | 1999-12-21 | 2001-06-28 | Yale University | Survivin promotion of angiogenesis |
WO2001057206A2 (en) | 2000-02-03 | 2001-08-09 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
EP1272630A2 (en) * | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
NZ522045A (en) * | 2000-03-30 | 2007-05-31 | Whitehead Biomedical Inst | RNA sequence-specific mediators of RNA interference |
HUP0302779A3 (en) * | 2000-06-23 | 2005-12-28 | Schering Ag | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
US20020132788A1 (en) * | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
US20020173478A1 (en) * | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
ES2728168T3 (es) * | 2000-12-01 | 2019-10-22 | Max Planck Gesellschaft | Moléculas pequeñas de ARN que median en la interferencia de ARN |
EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
US20050159380A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA) |
WO2003046173A1 (fr) * | 2001-11-28 | 2003-06-05 | Center For Advanced Science And Technology Incubation, Ltd. | Systeme d'expression d'arn si et procede de production de cellules d'inactivation de genes fonctionnelles et analogues au moyen de ce systeme |
AU2003237686A1 (en) | 2002-05-24 | 2003-12-12 | Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
US20040115640A1 (en) * | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of angiopoietin-2 expression |
EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
DE602004028587D1 (de) * | 2003-01-16 | 2010-09-23 | Univ Pennsylvania | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1 |
CA2522730A1 (en) | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2 |
-
2004
- 2004-04-19 CA CA002522730A patent/CA2522730A1/en not_active Abandoned
- 2004-04-19 US US10/827,759 patent/US7994305B2/en not_active Expired - Fee Related
- 2004-04-19 WO PCT/US2004/012072 patent/WO2004094606A2/en active Search and Examination
- 2004-04-19 MX MXPA05011221A patent/MXPA05011221A/es active IP Right Grant
- 2004-04-19 JP JP2006513132A patent/JP2006523464A/ja active Pending
- 2004-04-19 EP EP04760012A patent/EP1615943A4/en not_active Withdrawn
- 2004-04-19 AU AU2004233043A patent/AU2004233043A1/en not_active Abandoned
-
2011
- 2011-06-20 US US13/163,806 patent/US20120039986A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040248174A1 (en) | 2004-12-09 |
EP1615943A2 (en) | 2006-01-18 |
CA2522730A1 (en) | 2004-11-04 |
EP1615943A4 (en) | 2006-08-16 |
US20120039986A1 (en) | 2012-02-16 |
WO2004094606A2 (en) | 2004-11-04 |
WO2004094606A3 (en) | 2005-09-15 |
JP2006523464A (ja) | 2006-10-19 |
US7994305B2 (en) | 2011-08-09 |
AU2004233043A1 (en) | 2004-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05011221A (es) | Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi. | |
EP2345718A3 (en) | Compositions and methods for siRNA inhibition of angiogenesis | |
MXPA05007651A (es) | Composiciones y metodos para la inhibicion por arnsi de la molecula de adhesion intercelular-1. | |
AU2013296321B2 (en) | Modified RNAi agents | |
MX2010009195A (es) | Rnas ultrapequeños como antagonistas del receptor tipo toll-3. | |
SG171676A1 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
WO2007067981A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2007022470A3 (en) | Methods and compositions for treating neurological disease | |
SG165394A1 (en) | Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification | |
SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
TNSN08252A1 (en) | Sirna anti myosine va et depigmentation de la peau | |
MX2009006310A (es) | Composiciones y metodos para tratar trastornos musculares y cardiovasculares. | |
WO2008045576A3 (en) | Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases | |
WO2020198509A3 (en) | Modified oligonucleotides with increased stability | |
JP5941842B2 (ja) | 優性アレル発現抑制剤 | |
JP6137484B2 (ja) | 遺伝子発現抑制用二本鎖核酸分子 | |
WO2007117121A3 (en) | Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent | |
AU2003238804A8 (en) | Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis | |
WO2005018534A3 (en) | Methods and compositions for rna interference | |
WO2006036736A3 (en) | Reproductive ablation constructs | |
WO2011065677A3 (ko) | 암 치료용 약학 조성물 | |
EP1697498A4 (en) | KINASESUPPRESSOR OF RAS INACTIVATION FOR THE THERAPY OF RAS-ASSOCIATED TUMORGENESIS | |
WO2023081500A3 (en) | RNAi OLIGONUCLEOTIDE CONJUGATES | |
WO2006061418A3 (en) | Methods and agents useful in treating conditions characterized by mucus hyperproduction/hypersecretion | |
WO2005026359A3 (en) | The use of eukaryotic genes affecting spindle formation or microtubule function during cell division for diagnosis and treatment of proliferative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |